Neurocritical care constitutes a specialized medical domain dedicated to addressing and treating patients afflicted with critical neurological conditions. These conditions often entail severe injuries or diseases impacting the brain, spinal cord, or peripheral nerves, necessitating immediate and intensive medical attention. The principal objective of neurocritical care revolves around averting secondary brain damage and optimizing neurological function in individuals grappling with life-threatening neurological ailments. This entails meticulous monitoring of vital signs, neurological status, and intracranial pressure, alongside prompt interventions to forestall complications like cerebral edema, ischemia, or hemorrhage. Neurocritical care teams typically comprise multidisciplinary experts, including neurologists, neurosurgeons, critical care physicians, nurses, respiratory therapists, and pharmacists, collaborating synergistically to furnish comprehensive care to patients grappling with complex neurological disorders. Common conditions managed within neurocritical care units encompass traumatic brain injury, subarachnoid hemorrhage, ischemic and hemorrhagic stroke, status epilepticus, spinal cord injury, and severe neurological infections. Treatment modalities may entail neuroprotective measures, mechanical ventilation, intracranial pressure monitoring, vasopressor therapy, and neurosurgical interventions like decompressive craniectomy or clot evacuation. Neurocritical care also assumes a pivotal role in aiding patients through the acute phase of their illness and facilitating their transition to rehabilitation services or long-term care facilities. Additionally, neurocritical care research contributes to advancements in comprehending the pathophysiology of neurological diseases and devising innovative treatments to augment patient outcomes.
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States